A customized survey of 14 questions covering the previous 7 days was incorporated into each clinic visit. The PRO-CTCAE items chosen represented the symptoms and related severities most often associated with ICI treatment. HSPC may have immunologic differences compared with castration-resistant prostate cancer, providing a therapeutic opportunity for ICI in this earlier disease setting. To address this, we incorporated selected items from the NCI’s PRO-CTCAE into a phase II clinical trial ( Identifier: NCT02020070) evaluating the efficacy and safety of ipilimumab, a humanized monoclonal antibody directed to the cytotoxic T-lymphocyte–associated protein 4 (CTLA-4) in combination with standard androgen deprivation therapy (ADT) in patients with hormone-sensitive prostate cancer (HSPC). Limited data are available about the benefit of using PRO-CTCAE to monitor irAEs resulting from treatment with ICIs in clinical trials.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |